B. Hughes, “Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6”, J of Skin, vol. 7, no. 2, p. s175, Mar. 2023.